Next Article in Journal
TXH11106: A Third-Generation MreB Inhibitor with Enhanced Activity against a Broad Range of Gram-Negative Bacterial Pathogens
Next Article in Special Issue
Prevalence and Antimicrobial Resistance of Virulent Listeria monocytogenes and Cronobacter sakazakii in Dairy Cattle, the Environment, and Dried Milk with the In Vitro Application of Natural Alternative Control
Previous Article in Journal
Exploring the Antimicrobial Stewardship Educational Needs of Healthcare Students and the Potential of an Antimicrobial Prescribing App as an Educational Tool in Selected African Countries
Previous Article in Special Issue
The Emergence and Dissemination of Multidrug Resistant Pseudomonas aeruginosa in Lebanon: Current Status and Challenges during the Economic Crisis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 11
Issue 5
10.3390/antibiotics11050692
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Whole-Genome Characterisation of ESBL-Producing E. coli Isolated from Drinking Water and Dog Faeces from Rural Andean Households in Peru

by
Maria Luisa Medina-Pizzali
1,
Apoorva Venkatesh
2,3,
Maribel Riveros
4,
Diego Cuicapuza
5,
Gabriela Salmon-Mulanovich
1,6,
Daniel Mäusezahl
1,2,3 and
Stella M. Hartinger
1,2,3,*
1
Research Unit in Integral Development, Environment and Health, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima 15102, Peru
2
Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland
3
University of Basel, 4001 Basel, Switzerland
4
School of Medicine, Universidad Peruana Cayetano Heredia, Lima 15102, Peru
5
Laboratory of Microbial Genomics, Department of Cellular and Molecular Sciences, School of Science and Philosophy, Universidad Peruana Cayetano Heredia, Lima 15102, Peru
6
Institute for Earth, Nature and Energy, Pontificia Universidad Católica del Perú, Lima 15088, Peru
*
Author to whom correspondence should be addressed.
Antibiotics 2022, 11(5), 692; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050692
Submission received: 2 April 2022 / Revised: 6 May 2022 / Accepted: 11 May 2022 / Published: 20 May 2022
(This article belongs to the Special Issue Antibiotic Resistance and Infectious Diseases: A One Health Perspective)
Browse Figure
Review Reports Versions Notes

Abstract

:
E. coli that produce extended-spectrum β-lactamases (ESBLs) are major multidrug-resistant bacteria. In Peru, only a few reports have characterised the whole genome of ESBL enterobacteria. We aimed to confirm the identity and antimicrobial resistance (AMR) profile of two ESBL isolates from dog faeces and drinking water of rural Andean households and determine serotype, phylogroup, sequence type (ST)/clonal complex (CC), pathogenicity, virulence genes, ESBL genes, and their plasmids. To confirm the identity and AMR profiles, we used the VITEK®2 system. Whole-genome sequencing (WGS) and bioinformatics analysis were performed subsequently. Both isolates were identified as E. coli, with serotypes -:H46 and O9:H10, phylogroups E and A, and ST/CC 5259/- and 227/10, respectively. The isolates were ESBL-producing, carbapenem-resistant, and not harbouring carbapenemase-encoding genes. Isolate 1143 ST5259 harboured the astA gene, encoding the EAST1 heat-stable toxin. Both genomes carried ESBL genes (blaEC-15, blaCTX-M-8, and blaCTX-M-55). Nine plasmids were detected, namely IncR, IncFIC(FII), IncI, IncFIB(AP001918), Col(pHAD28), IncFII, IncFII(pHN7A8), IncI1, and IncFIB(AP001918). Finding these potentially pathogenic bacteria is worrisome given their sources and highlights the importance of One-Health research efforts in remote Andean communities.

Graphical Abstract

1. Introduction

Antimicrobial resistance (AMR)—particularly in the Enterobacteriaceae family—has become a problem of great relevance worldwide due to its increasing prevalence, and the emergence of multiple-drug-resistant strains AMR can affect everyone, irrespective of age. It is estimated that, in 2019, 4.95 million people died from illnesses associated with bacterial AMR. Of those, 1.27 million deaths, mostly in low- and middle-income countries (LMICs), were directly attributable to bacterial AMR [1]. Enterobacteria are the most important etiological agents of serious hospital-acquired and community-onset bacterial infections in humans [2,3,4,5]. In South America, resistance to β-lactam antibiotics and fluoroquinolones is a major problem when treating enterobacterial infections [6]. In addition, reports of the emergence of colistin resistance in this region have been recently published [7,8]. South American countries show some of the highest rates of AMR in Enterobacteriaceae worldwide. Huge socioeconomic differences, broad access to antimicrobials, and ineffective health systems and sanitation problems favour the emergence and spread of resistant bacterial strains [6]. In this region, antibiotic use is widespread in human medicine and animal production; thus antibiotic residues and resistant enterobacteria and AMR genes have been detected in soil, water from different environs, agricultural products (produce), and livestock. In rural Latin America, anthropogenic activities such as animal husbandry, fish farming, and agriculture were identified as drivers for antimicrobial resistance dissemination [9]. The most frequent animal contributions were the carriage and/or transfer of antimicrobial resistance determinants, the inadequate or unregulated use of veterinary antimicrobials, and the spread of resistant bacteria throughout the food supply chain via foods of animal origin [10]. Water was the most frequently identified among the environmental contributors to AMR spread in Andean Peru [9,11,12].
β-Lactamases are the leading cause of resistance to β-lactam antibiotics, and β-lactamase production is the primary mechanism of antibiotic resistance in Escherichia coli [13]. Among β-lactamases, extended-spectrum β-lactamases (ESBLs) that mediate resistance to all penicillins, third-generation cephalosporins, and aztreonam are of utmost importance, given that they substantially reduce the available antibiotic treatment options [14]. ESBLs include the extended-spectrum TEM-, SHV-, OXA-, and cefotaxime (CTX)-M type enzymes [15], while E. coli that produce CTX-Ms are most commonly associated with ESBLs [16]. AmpC β-lactamases —which function as cephalosporinases— are also clinically important. They hydrolyse cephamycins and other extended-spectrum cephalosporins and are poorly inhibited by clavulanic acid; in some cases, they confer resistance to carbapenems [17].
In Peru, previous studies have investigated ESBLs in enterobacteria isolated from clinical, community, and peri-urban settings. However, few reports have characterised ESBL-producing enterobacteria at the molecular level, and if so, mostly in clinical settings [18,19,20,21,22]. Using molecular methods, we previously characterised ESBL-producing enterobacteria from rural Andean communities [12,23]. However, literature on genomic characterisation of ESBL bacteria in Peru is very scarce [24,25,26]. The present study is the first report of the whole-genome characterisation of ESBL-producing E. coli isolates from water and farm/companion animals in a rural Andean setting in Peru. This study aims to confirm the identity and AMR profile and determine the serotype, phylogroup, sequence type (ST) and clonal complex (CC), pathogenicity, virulence genes, ESBL genes, and type of plasmids for ESBL-producing E. coli isolates.

2. Materials and Methods

2.1. Study Setting and Design

Hartinger et al. studied the dissemination pathways of AMR in humans, animals, and the environment in the Cajamarca Region in the northern highlands of Peru. The cross-sectional study design and sampling scheme are described elsewhere [23]. In brief, they sampled 40 households. Their study collected two rectal or cloacal swabs of fresh stool samples from a domestic animal (dog, cat) and/or a farm animal (cow, pig, fowl) from each household (n = 80). Additionally, two water samples per household were collected, one from the household’s drinking water (DW) source and/or one from the household’s primary water source (n = 80). The two ESBL-positive isolates analysed in the present study originated from two out of 40 households sampled. They were isolated from one water sample and one dog faeces sample, as shown in Supplementary Materials Figure S1.

2.2. Households’ Characteristics

Hartinger et al. found only one ESBL isolate from a dog and an ESBL isolate from the DW source from two homes [23]. In these households, animals were allowed to roam freely in the kitchen and courtyard, and their faeces were found in both areas. Both homes used piped water from the public water network system but had no sewage system, as they had installed latrines instead.

2.3. Microbiological Identification and Antimicrobial Susceptibility Testing

The microbiological identification and the antimicrobial susceptibility testing were performed using a VITEK® 2 Compact automated system (bioMérieux, Marcy l’Etoile, France). A colorimetric reagent card (GN) to identify the most significant fermenting and non-fermenting Gram-negative bacilli was used according to the manufacturer’s instructions. AST-N249 cards were prepared according to the manufacturer’s instructions. The minimum inhibitory concentrations for the following antimicrobials were recorded (ampicillin/sulbactam (SAM), piperacillin/tazobactam (TZP), cefazolin (CFZ), cefuroxime (CXM), cefotaxime (CTX), ceftazidime (CAZ), cefepime (FEP), ertapenem (ETP), imipenem (IPM), meropenem (MEM), amikacin (AMK), gentamicin (GEN), ciprofloxacin (CIP), colistin (CST), and tigecycline (TGC). Previously [23], antimicrobial susceptibility testing for other antimicrobials has been performed using commercial discs [27]; Escherichia coli ATCC 25922 was used as a reference strain for quality assurance of the susceptibility testing of E. coli.

2.4. Phenotypical and Molecular Identification of ESBL-Producing Ability

The phenotypical ESBL-producing ability of the isolates was determined using the Jarlier method [28] for the following antibiotics: aztreonam (5 µg disk), ceftazidime (30 µg disk), cefotaxime (30 µg disk), ceftriaxone (30 µg disk), amoxicillin/clavulanic acid (30 µg disk) and cefepime (30 µg disk), and confirmed by the combined disc method [27]. Further molecular confirmation was performed using conventional polymerase chain reaction PCR. These procedures have been described elsewhere [23]. Briefly, genes encoding TEM-, SHV-, OXA-, and CTX-M-type β-lactamases (blaTEM, blaSHV, blaOXA, blaCTX-M-U, blaCTX-M-2, blaCTX-M-3, blaCTX-M-8, blaCTX-M-9, blaCTX-M-10) were PCR-amplified using the primers shown previously [23].

2.5. Genome Sequencing and Bioinformatic Analysis

The genomic DNA was extracted from overnight cultures using the GeneJET genomic DNA purification kit (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions. DNA concentration was evaluated by Qubit® 4.0 fluorometer (Life Technologies, Carlsbad, CA, USA). The genomic library was constructed using a Nextera XT DNA Library Preparation Kit (Illumina, Inc., San Diego, CA, USA) and subsequently sequenced using a 2 × 250 paired-end library on a MiSeq platform (Illumina). The quality control of each sequence was evaluated using Fastqc v0.11.5 [29], and Trimmomatic v0.38 [30] was used to remove adapters and filter low-quality reads. The reads were assembled de novo using SPAdes v.3.15.2 [31]. The bioinformatic analysis was carried out using the tools available at the Center of Genomic Epidemiology (www.genomicepidemiology.org) (accessed on 1 October 2021), setting identity at ≥90% and coverage at ≥90%. We performed E. coli serotyping (SerotypeFinder v.2.0), in silico phylogenetic typing (ClermonTyping (https://github.com/A-BN/ClermonTyping) (accessed on 1 January 2022), multilocus sequence typing (MLST v.2.0), pathogenicity (Pathogen Finder v.1.1), virulence genes detection (VirulenceFinder v.2.0), plasmid replicon typing (PlasmidFinder v.2.1 and MobileElementFinder v.1.0), and ESBL genes detection using ABRicate v.1.0.1 (https://github.com/tseemann/abricate) (accessed on 1 January 2022) NCBI and ResFinder databases. Raw Illumina reads were uploaded to GenBank under BioProject PRJNA816508.The complete outputs for all the results of the bioinformatic tools are shown in Supplementary Materials Table S2.

3. Results

3.1. Microbiological Identification and Antimicrobial Susceptibility Testing of the E. coli Isolates

For this analysis, only ESBL-phenotypically-positive isolates obtained in the mother study were included, one from dog faeces (Isolate 1143) and one from the household’s DW source (Isolate 1144). Isolates 1143 and 1144 were identified as E. coli strains with a 93% and 96% probability using VITEK®2 (bioMérieux, Marcy l’Etoile, France) automated reading and further confirmed by WGS.
Based on the VITEK®2 system, both isolates were resistant to SAM (combined effect); cephalosporins CFZ, CXM, and CTX; TZP (β-lactam/β-lactamase inhibitor combination); and MEM (a carbapenem). However, only Isolate 1143 was resistant to important cephalosporins CAZ and FEP and the combination antibiotic SXT. On the other hand, only Isolate 1144 was resistant to GEN and CIP, while 1143 was not. We compared the VITEK®2 automated readings for antimicrobial susceptibility to the disk diffusion assay results, as shown in Supplementary Materials Table S1. It is noteworthy that Isolate 1144 showed resistance to FEP by the disk diffusion method, contrary to the results obtained using the automated VITEK®2 platform. The VITEK®2 system identified Isolate 1143 as an ESBL producer. Isolate 1144, however, was characterised as ESBL negative based on the MIC results, which were interpreted automatically by the system based on the VITEK®2 breakpoints (see Supplementary Materials Table S1).

3.2. Detection of ESBL-Encoding Genes by PCR and Whole-Genome Sequencing Analysis (WGS)

Detection of the most common β-lactamase-encoding genes (blaTEM, blaSHV, blaOXA, and blaCTX-M) was carried out using PCR. None of the isolates showed amplification for blaSHV, and blaOXA genes, but both harboured blaTEM and blaCTX-M genes. WGS analysis using Resfinder and NCBI identified the presence of genes encoding resistance to cephalosporins (blaCTX-M-8, blaCTX-M-55, blaEC-15), broad-spectrum β-lactamases (blaTEM-1), tetracyclines (tet(B), tet(M)), aminoglycosides (aac(3)-Iid, aph(3’)-Iia, aph(3’’)-Ib, aph(6)-Id, aadA1 and aadA2), sulphonamides (sul3), phenicols (floR, cmlA1), fosfomycin (fosA3), quinolone (qnrB19), and trimethoprim (dfrA12), as shown in Table 1. The genotypic resistance of both isolates correlated with their phenotypical resistance, except for MEM; the resistance to this carbapenem was only phenotypically observed.
Genomic analysis using MLST 2.0 indicated that the E. coli Isolates 1143 and 1144 belonged to ST5259 and ST227, respectively, and 1144 belonged to CC 10. According to the genomes’ analysis using the ClermontTyping tool, the 1143 and 1144 isolates corresponded to the phylogenetic groups E and A, respectively. Using SerotypeFinder v.2.0, Isolate 1143 was classified as serotype -:H46, whereas Isolate 1144 belonged to serotype O9:H10, as presented in Table 1.

3.3. Pathogenicity, Virulence Genes, and Type of Plasmids

Using Pathogenfinder 1.1 and VirulenceFinder 2.0, both isolates were identified as likely human pathogens, but Shiga-toxin genes were not detected in their genomes. A total of 28 different virulence genes were detected from the E. coli genomes. The colicin ia (cia) virulence gene was detected in both E. coli isolates. Other prevalent virulent genes included: astA, iroN, chuA, gad, ompT, capU, cea, fyuA, sitA, irp2 iutA, and terC. The astA gene (gene product: EAST1 heat-stable toxin) was found in Isolate 1143 only.
Using the PlasmidFinder 2.1 and the MobileElementFinder 1.0 tools, four plasmids were detected for Isolate 1143, IncR (harbouring the aph(3’’)-Ib and aph(6)-Id aminoglycoside resistance genes), IncFIC(FII) (harbouring the florfenicol/chloramphenicol resistance floR gene), IncI1 (carrying the cia virulence gene), and IncFIB(AP001918). On the other hand, for Isolate 1144, five plasmids were identified, Col(pHAD28) (harbouring the qnrB19 ciproflaxacin resistance gene), IncFII, IncFII(pHN7A8), IncI1, and IncFIB(AP001918).

4. Discussion

We confirmed the identity of the two enterobacteria isolates (1143 and 1144) as E. coli; Isolate 1143—obtained from dog faeces—was an atypical non-lactose fermenter. Lactose-negative uropathogenic E. coli strains have been recently isolated from dogs in Brazil [32], and they cause urinary tract infections in humans [33]. Further, lactose-negative E. coli are usually enteroinvasive (EIEC), are closely related to Shigella spp., and produce a dysenteric form of diarrhoea in humans [34]. Both isolates were likely human pathogens, with serotypes -:H46 and O9:H10, respectively. The E. coli O9:H10 serotype has been listed among the typical enteroaggregative (EAEC) E. coli serotypes in Brazil [35], and the same serotype was identified among samples of Shiga-toxin-producing E. coli (STEC) and Enteroaggregative E. coli (EAEC) from Mexico [36].
Both isolates were confirmed as ESBL producers given their genomes encoded ESBL genes (blaCTX-M-8, blaCTX-M-55, blaEC-15), contrary to the VITEK®2 automatised system’s classification of Isolate 1144 as a non-ESBL producer. The VITEK®2 ESBL test has a varying sensitivity for detecting ESBL-producing enterobacteria correctly; it ranges between 86% and 98.1% [37,38]. The VITEK®2 AST N249 card used in our study identified Isolate 1143 as an ESBL producer, but not Isolate 1144, since it was not resistant to FEP and CAZ. However, Isolate 1144 showed a phenotypical resistance to other oxyimino cephalosporins CXM and CTX.
Isolate 1143 and Isolate 1144 belonged to phylogroups E and A, respectively. Phylogroup E includes the O157:H7 EHEC lineage, which is only a small subset of the whole genetic diversity found within the group. Phylogroup-E strains are rarely isolated compared to other phylogroup strains. They have been isolated from animals, the environment, and humans, and virulent/resistant strains are linked to humans [39]. Thus, finding an ESBL-producing, potentially pathogenic, phylogroup-E isolate in dog faeces points to a probable transmission route from humans. On the other hand, most phylogroup-A strains are human commensals and can be found in wastewater [40] and animals, especially poultry [41]. Notably, in our setting, backyard chicken farming is widespread (83% of households), and farm animals, in general, are administered antibiotics by the owners without prescription nor technical supervision (unpublished data from our research group). Other studies carried out in rural locations in Peru show similar findings [42,43]. Chickens roam freely, and household members are in contact with their animals and their scattered faeces. On the other hand, the piped water supply and the soil near the houses were contaminated with faecal coliforms originating from the environment, humans, or animals [23]. The fact that both isolates in this study displayed resistance to carbapenems is of great concern, given that this “third line” antimicrobial medication is exclusively for human use [44]. Thus, the ESBL/AmpC carbapenem-resistant E. coli isolates found in DW and dog faeces could originate from other farm animals or humans and be transmitted by different pathways, as shown by Hartinger et al. in our study area [23].
Isolates 1143 and 1144 belonged to ST/CC 5259/- and 227/10, respectively. We found that E. coli ST227 are considerably common and have been frequently reported around the world. In the public database EnteroBase (https://enterobase.warwick.ac.uk) (accessed on 1 February 2022), we found 84 publicly available E. coli ST227 genome assemblies from human, animal, and environmental sources. In Tunisia, an ST227 carbapenem-resistant E. coli isolate of human origin was reported in 2016, carrying the blaOXA-48, blaCTX-M-15, blaTEM, and blaOXA-1 genes [45]. A carbapenem-resistant E. coli isolate of the ST227 lineage was isolated from clinical samples in Lebanon, carrying the blaOXA-48 and the blaTEM-1 genes [46]. E. coli ST5259 are scarce; only two were found in EnteroBase, one of them originated from poultry in Ecuador and the other from humans in the United States of America. In China, an E. coli ST5259 genome of human origin was mentioned as part of BioProject PRJNA400107, being reported along with other E. coli genomes as carriers of the mcr-1 gene, which is a plasmid-mediated colistin resistance gene [47].
Many of the identified virulence genes were associated with iron acquisition systems, and a small part was associated with toxin production, metal resistance (tellurite), and other virulence determinants, as shown in Supplementary Materials Table S2. The cia gene—involved in killing other bacteria—was found in both isolates. The iron uptake genes detected were: iroN, chuA, fyuA, iutA, and sitA. The chuA gene encodes an outer membrane hemin receptor, and the fyuA gene encodes the yersiniabactin receptor, and both contribute most during infection of the urinary tract by uropathogenic E. coli [48]. The chuA gene was detected in Isolate 1143, whereas the fyuA gene was found in Isolate 1144 along with the other iron acquisition genes. This flags Isolate 1144 as a possible uropathogenic strain, given it harboured many genes that enable iron uptake, best suited for iron-deprived environments such as human urine [49]. On the other hand, Isolate 1143 harboured the astA gene, encoding the EAST1 heat-stable toxin, which is associated with enteroaggregative E. coli (EAEC) in humans and enterotoxigenic E. coli (ETEC) in porcines [50]. None of the isolates’ genomes harboured Shiga-toxin genes.
The blaCTX-M-55 is one of the most abundant ESBL genes in the Enterobacteriaceae family, with a rising prevalence in E. coli from livestock and humans, especially in China [51,52]. It is usually carried by plasmids, but it has also been found chromosomally [52]. In Canada, enterobacteria isolated from turkeys carried the blaCTX-M-55 gene mediated by IncF plasmids [53]. In Japan, the blaCTX-M-8 gene was found in E. coli from humans and retail chicken meat, and its transmission was associated with IncI1 plasmids [54].
Unlike blaCTX-M-55 and blaCTX-M-8, which code for Class A ESBL, the blaEC-15 gene product belongs to the Class C β-lactamases [55], also known as AmpC-type β-lactamases. In comparison to ESBL (including Class A β-lactamases), AmpC-type β-lactamases hydrolyse broad- and extended-spectrum cephalosporins (cephamycins as well as oxyimino-β-lactams) but are not inhibited by clavulanic acid or other β-lactamase inhibitors. EC β-lactamases—encoded in blaEC genes—are a specific type of AmpC β-lactamases found in E. coli [56]. In a recent One-Health study in Canada, the blaEC-15 gene was detected in E. coli isolates from different human, animal, and environmental sources. It did not occur in all isolates, having a prevalence of 16% [57] The fact that both isolates in our study carried genes for Class A ESBL and AmpC β-lactamases has great clinical importance, given that AmpC/ESBL E. coli cannot be treated with clavulanic acid, which complicates the treatment [58]. However, we did not include a cephalosporin/clavulanic acid combination in the disc diffusion assay, so resistance to clavulanic acid was not phenotypically confirmed. Further, both isolates expressed resistance to other antibiotics such as fluoroquinolones and a carbapenem, narrowing treatment options even further. According to Guzmán-Blanco et al. [59], in Latin America, the rates of nosocomial infection caused by ESBL-producing enterobacteria—especially CTX-M enzyme producers—are higher than in other regions. A One-Health-based study in Brazil—the biggest country in the region—showed that ESBL-producing E. coli carrying a diversity of blaCTX-M gene variants and mcr-1 genes are endemic across their territory at the interface between humans and animals [60]. ESBL-producing enterobacteria can also be resistant to cefepime and exhibit resistance to fluoroquinolones and ampicillin/sulbactam, as well as to aminoglycosides and piperacillin/tazobactam. Fortunately, more than 90% of ESBL-producing enterobacteria are still susceptible to carbapenems [59], although reports of carbapenem-resistant enterobacteria alarmingly increase in Latin American countries [61].
Despite the phenotypic resistance to meropenem of both isolates in our study, we did not find evidence of well-known carbapenemase-encoding genes—blaKPC, blaNDM, blaNDM, blaIMP, blaVIM and blaOXA-48—or their variants [62]. Thus, non-carbapenemase mechanisms could be suspected for the isolates in our study. For instance, point mutations in porin genes reduce membrane permeability to carbapenems, in combination with hyperproduction of the β-lactamase AmpC or ESBL. Therefore, the isolates could be characterised as non-carbapenemase, carbapenem-resistant E. coli [63,64]. In Singapore, the emergence of this type of bacteria in clinical settings was suggested to result from selective antibiotic pressure along with de novo mutations or genetic reassortment in carbapenem-sensitive enterobacteria [65].
Plasmids play a major role in the dissemination of AMR genes in Gram-negative bacteria. Usually, they harbour multiple physically connected genetic determinants, conferring resistance to different classes of antibiotics simultaneously, such as extended-spectrum β-lactams, carbapenems aminoglycosides, sulfonamides, and quinolones [66,67]. Plasmid families, including IncF, IncI1, IncI2, IncX, IncA/C, and IncHI2, play an important part in ESBL gene spread [67]. It is noteworthy that both E. coli genomes carried Incl1 plasmid. Our findings show that for Isolate 1143, some AMR genes were harboured in plasmids or other mobile genetic elements, e.g., aminoglycoside resistance genes in the IncR plasmid and the blaTEM-1 gene (resistance to ampicillins) were found to be carried in the Tn2 transposon (https://transposon.lstmed.ac.uk/tn-registry) (accessed on 1 January 2022). Conversely, for Isolate 1144, the ciprofloxacin resistance gene (qnrB19) was carried by Col440I; this is a plasmid recently associated with enterobacteria-carrying ESBL and carbapenemases genes isolated from environment and humans in South Africa [68]. In our analysis, we found that many AMR genes appeared to be inserted in the chromosome—such as blaCTX-M-55 and blaCTX-M-8—pointing to the mobility of these genes from mobile genetic elements to the chromosome and vice versa and between different plasmids [69].
Our study has some limitations. The presence of AMR genes harboured in plasmids points to horizontal transfer of AMR determinants. However, conjugation assays should be performed for these isolates to confirm the transfer of genes via plasmids to other bacteria. In addition, isolates were not tested to phenotypically confirm AmpC, pathogenicity, and/or EAST1 toxin production. Due to laboratory limitations and restrictions, it was impossible to perform these confirmatory assays. Another limitation is the low number of isolates available for characterisation, which may have limited the scope of detection of important resistance/virulence genes and plasmids.

5. Conclusions

Isolates 1143 and 1144 were identified as ESBL-producing E. coli, with serotypes -:H46 and O9:H10; phylogroups E and A, and ST/CC 5259/- and 227/10, respectively. They were characterised as potential human pathogens, and they carried multiple virulence genes; Isolate 1143 ST5259 harboured the astA gene, encoding the EAST1 heat-stable toxin. Both genomes were carriers of a blaEC-15 gene (AmpC), displaying carbapenem resistance, but not harbouring carbapenemase genes. Other ESBL genes (blaCTX-M-8 and blaCTX-M-55) among various AMR genes were detected, mainly located in plasmids or the chromosome. E. coli of the ST227 lineage were reported in other countries, while E. coli ST5259 reports were rare. Both isolates were found in a remote area in the highlands of Peru, which is of public health concern considering the likely anthropogenic origin derived from incorrect and often unrestricted use of antibiotics in both humans and livestock. Our results can help identify and track E. coli strains that pose a risk to human, animal, and environmental health in rural Andean communities. The E. coli isolates originated from an animal and DW, highlighting the importance of comprehensive research for preventive action along the One-Health continuum in isolated Andean communities. The sharing of living spaces between humans and animals and the use of contaminated DW could facilitate the transfer of these pathogens to all environs in the community. Thus, new research paths to limit the spread of AMR should focus on the epidemiology of ESBL/AmpC E. coli, particularly carbapenem-resistant strains.

Supplementary Materials

The following supporting information can be downloaded at: https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/antibiotics11050692/s1, Figure S1: Obtention of the E. coli isolates 1143 and 1144; Table S1: Antibiotic susceptibilitya profile for E. coli Isolates 1143 and 1144 determined by the VITEK®2 system and compared to the disk diffusion assay resultsb; Table S2: Outputs of bioinformatic tools.

Author Contributions

Conceptualisation, S.M.H., M.R. and D.C.; methodology, M.R. and D.C.; bioinformatic analysis, D.C. and M.L.M.-P.; visualisation, D.C.; writing—original draft preparation, M.L.M.-P., A.V. and D.C.; writing—review and editing, M.L.M.-P., A.V., D.C., M.R., S.M.H., G.S.-M. and D.M.; supervision, D.M., S.M.H. and G.S.-M.; funding acquisition, S.M.H. and D.M. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Novartis Foundation (Grant Number 18A059), and D.C. was supported by a scholarship from Emerge, the Emerging Diseases Epidemiology Research Training D43 TW007393 training grant awarded by the Fogarty International Center of the US National Institutes of Health.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board for humans and animal subjects of the Universidad Peruana Cayetano Heredia, Protocol Codes 418-16-18 and 010-03-20.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The raw reads and assembled data have been submitted to National Center for Biotechnology Information (NCBI) under BioProject Number PRJNA816508.

Acknowledgments

We thank Pablo Tsukayama for his comments on the manuscript.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Murray, C.J.; Ikuta, K.S.; Sharara, F.; Swetschinski, L.; Robles Aguilar, G.; Gray, A.; Han, C.; Bisignano, C.; Rao, P.; Wool, E.; et al. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. Lancet 2022, 399, 629–655. [Google Scholar] [CrossRef]
  2. D’Agostino, M.; Cook, N. Foodborne Pathogens. In Encyclopedia of Food and Health; Caballero, B., Finglas, P., Toldrá, F., Eds.; Academic Press: Cambridge, MA, USA, 2015; pp. 83–86. [Google Scholar]
  3. Guentzel, M.N. Escherichia, Klebsiella, Enterobacter, Serratia, Citrobacter, and Proteus. In Medical Microbiology; Baron, S., Ed.; University of Texas Medical Branch at Galveston: Galveston, TX, USA, 1996. [Google Scholar]
  4. Larsson, D.G.J.; Flach, C.-F. Antibiotic Resistance in the Environment. Nat. Rev. Microbiol. 2021, 20, 257–269. [Google Scholar] [CrossRef] [PubMed]
  5. Laxminarayan, R.; Duse, A.; Wattal, C.; Zaidi, A.K.M.; Wertheim, H.F.L.; Sumpradit, N.; Vlieghe, E.; Hara, G.L.; Gould, I.M.; Goossens, H.; et al. Antibiotic Resistance-the Need for Global Solutions. Lancet Infect. Dis. 2013, 13, 1057–1098. [Google Scholar] [CrossRef] [Green Version]
  6. Bonelli, R.R.; Moreira, B.M.; Picão, R.C. Antimicrobial Resistance among Enterobacteriaceae in South America: History, Current Dissemination Status and Associated Socioeconomic Factors. Drug Resist. Updat. 2014, 17, 24–36. [Google Scholar] [CrossRef]
  7. Mendes Oliveira, V.R.; Paiva, M.C.; Lima, W.G. Plasmid-Mediated Colistin Resistance in Latin America and Caribbean: A Systematic Review. Travel Med. Infect. Dis. 2019, 31, 101459. [Google Scholar] [CrossRef]
  8. Rapoport, M.; Faccone, D.; Pasteran, F.; Ceriana, P.; Albornoz, E.; Petroni, A.; Corso, A.; Maldonado, M.L.; Lucero, C.; Amalfa, F.; et al. First Description of Mcr-1-Mediated Colistin Resistance in Human Infections Caused by Escherichia coli in Latin America. Antimicrob. Agents Chemother. 2016, 60, 4412–4413. [Google Scholar] [CrossRef] [Green Version]
  9. Medina-Pizzali, M.L.; Hartinger, S.M.; Salmon-Mulanovich, G.; Larson, A.; Riveros, M.; Mäusezahl, D. Antimicrobial Resistance in Rural Settings in Latin America: A Scoping Review with a One Health Lens. Int. J. Environ. Res. Public Health 2021, 18, 9837. [Google Scholar] [CrossRef]
  10. Van Boeckel, T.P.; Pires, J.; Silvester, R.; Zhao, C.; Song, J.; Criscuolo, N.G.; Gilbert, M.; Bonhoeffer, S.; Laxminarayan, R. Global Trends in Antimicrobial Resistance in Animals in Low- And Middle-Income Countries. Science 2019, 365, eaaw1944. [Google Scholar] [CrossRef] [Green Version]
  11. Ahmad, I.; Malak, H.A.; Abulreesh, H.H. Environmental Antimicrobial Resistance and Its Drivers: A Potential Threat to Public Health. J. Glob. Antimicrob. Resist. 2021, 27, 101–111. [Google Scholar] [CrossRef]
  12. Larson, A.; Hartinger, S.M.; Riveros, M.; Salmon-Mulanovich, G.; Hattendorf, J.; Verastegui, H.; Huaylinos, M.L.; Mäusezahl, D. Antibiotic-Resistant Escherichia coli in Drinking Water Samples from Rural Andean Households in Cajamarca, Peru. Am. J. Trop. Med. Hyg. 2019, 100, 1363–1368. [Google Scholar] [CrossRef]
  13. Pitout, J.D.D. Extraintestinal Pathogenic Escherichia coli: An Update on Antimicrobial Resistance, Laboratory Diagnosis and Treatment. Expert Rev. Anti Infect. Ther. 2012, 10, 1165–1176. [Google Scholar] [CrossRef] [PubMed]
  14. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance; World Health Organization: Geneva, Switzerland, 2014. [Google Scholar]
  15. Sawa, T.; Kooguchi, K.; Moriyama, K. Molecular Diversity of Extended-Spectrum β-Lactamases and Carbapenemases, and Antimicrobial Resistance. J. Intensive Care 2020, 8, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Peirano, G.; Pitout, J.D.D. Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options. Drugs 2019, 79, 1529–1541. [Google Scholar] [CrossRef] [PubMed]
  17. Mohamudha, P.R.; Harish, B.N.; Parija, S.C. AmpC Beta Lactamases among Gram Negative Clinical Isolates from a Tertiary Hospital, South India. Braz. J. Microbiol. 2010, 41, 596–602. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Colquechagua Aliaga, F.; Andrade Sevilla, C.; Escalante Gonzales, E. Extended-Spectrum Beta-Lactamase (ESBL)-producing Enterobacteriaceae in Fecal Samples at the National Institute of Child Health, Peru. Rev. Peru Med. Exp. Salud Publica 2015, 32, 26–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Loyola, S.; Gutierrez, L.R.; Horna, G.; Petersen, K.; Agapito, J.; Osada, J.; Rios, P.; Lescano, A.G.; Tamariz, J. Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae in Cell Phones of Health Care Workers from Peruvian Pediatric and Neonatal Intensive Care Units. Am. J. Infect. Control 2016, 44, 910–916. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Garcia, C.; Hinostroza, N.; Astocondor, L.; Ochoa, T.; Jacobs, J. Characterization of ESBL-Producing Salmonella Enterica Serovar Infantis Infection in Humans, Lima, Peru. Am. J. Trop. Med. Hyg. 2019, 101, 746–748. [Google Scholar] [CrossRef]
  21. León-Luna, D.; Fajardo-Loyola, A.; Yareta-Yareta, J.; Burgos-Espejo, A.; Peralta-Siesquen, C.; Galarza-Pérez, M.; Marcos-Carbajal, P. Molecular Characterization of Multi-Resistant Enterobacteria in Two Departments of the Peruvian Jungle. Biomedica 2021, 41, 180–187. [Google Scholar] [CrossRef]
  22. Benavides, J.A.; Shiva, C.; Virhuez, M.; Tello, C.; Appelgren, A.; Vendrell, J.; Solassol, J.; Godreuil, S.; Streicker, D.G. Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Common Vampire Bats Desmodus Rotundus and Livestock in Peru. Zoonoses Public Health 2018, 65, 454–458. [Google Scholar] [CrossRef] [Green Version]
  23. Hartinger, S.M.; Medina-Pizzali, M.L.; Salmon-Mulanovich, G.; Larson, A.J.; Pinedo-Bardales, M.; Verastegui, H.; Riberos, M.; Mäusezahl, D. Antimicrobial Resistance in Humans, Animals, Water and Household Environs in Rural Andean Peru: Exploring Dissemination Pathways through the One Health Lens. Int. J. Environ. Res. Public Health 2021, 18, 4604. [Google Scholar] [CrossRef]
  24. Quino, W.; Hurtado, C.V.; Escalante-Maldonado, O.; Flores-León, D.; Mestanza, O.; Vences-Rosales, F.; Zamudio, M.L.; Gavilán, R.G. Multidrug Resistance of Salmonella infantis in Peru: A Study through next Generation Sequencing. Rev. Peru Med. Exp. Salud Publica 2019, 36, 37–45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Benavides, J.A.; Godreuil, S.; Opazo-Capurro, A.; Mahamat, O.O.; Falcon, N.; Oravcova, K.; Streicker, D.G.; Shiva, C. Long-Term Maintenance of Multidrug-Resistant Escherichia coli Carried by Vampire Bats and Shared with Livestock in Peru. Sci. Total Environ. 2022, 810, 152045. [Google Scholar] [CrossRef] [PubMed]
  26. Murray, M.; Salvatierra, G.; Dávila-Barclay, A.; Ayzanoa, B.; Castillo-Vilcahuaman, C.; Huang, M.; Pajuelo, M.J.; Lescano, A.G.; Cabrera, L.; Calderón, M.; et al. Market Chickens as a Source of Antibiotic-Resistant Escherichia coli in a Peri-Urban Community in Lima, Peru. Front. Microbiol. 2021, 12, 635871. [Google Scholar] [CrossRef] [PubMed]
  27. Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 30th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020. [Google Scholar]
  28. Lezameta, L.; Gonzáles-Escalante, E.; Tamariz, J.H. Comparison of four phenotypic methods to detect Extended-Spectrum Betalactamases. Rev. Peru Med. Exp. Salud Publica 2010, 27, 345–351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data. Available online: https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (accessed on 28 February 2022).
  30. Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A Flexible Trimmer for Illumina Sequence Data. Bioinformatics 2014, 30, 2114–2120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Bankevich, A.; Nurk, S.; Antipov, D.; Gurevich, A.A.; Dvorkin, M.; Kulikov, A.S.; Lesin, V.M.; Nikolenko, S.I.; Pham, S.; Prjibelski, A.D.; et al. SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing. J. Comput. Biol. 2012, 19, 455–477. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Siqueira, F.M.; de Carli, S.; Lopes, C.E.; Machado, L.; Vieira, T.R.; Pöppl, G.; Cardoso, M.R.I.; Zaha, A. Non-Lactose-Fermenting Uropathogenic Escherichia coli from Dogs: Virulence Profile Characterization. Lett. Appl. Microbiol. 2021, 72, 596–603. [Google Scholar] [CrossRef]
  33. Gajdács, M.; Ábrók, M.; Lázár, A.; Burián, K. Differential Epidemiology and Antibiotic Resistance of Lactose-Fermenting and Non-Fermenting Escherichia coli: Is It Just a Matter of Taste? Biol. Futur. 2020, 71, 175–182. [Google Scholar] [CrossRef]
  34. Food and Drug Administration. Chapter 4A: Diarrheagenic Escherichia coli. Available online: https://www.fda.gov/food/laboratory-methods-food/bam-chapter-4a-diarrheagenic-escherichia-coli (accessed on 1 January 2022).
  35. Ori, E.L.; Takagi, E.H.; Andrade, T.S.; Miguel, B.T.; Cergole-Novella, M.C.; Guth, B.E.C.; Hernandes, R.T.; Dias, R.C.B.; Pinheiro, S.R.S.; Camargo, C.H.; et al. Diarrhoeagenic Escherichia coli and Escherichia Albertii in Brazil: Pathotypes and Serotypes over a 6-Year Period of Surveillance. Epidemiol. Infect. 2019, 147, e10. [Google Scholar] [CrossRef] [Green Version]
  36. Navarro, A.; van der Ploeg, C.; Rogé, A.; Licona-Moreno, D.; Delgado, G.; Morales-Espinosa, R.; Cravioto, A.; Eslava, C. Diversity of Potentially Pathogenic Escherichia coli O104 and O9 Serogroups Isolated before 2011 from Fecal Samples from Children from Different Geographic Regions. Microorganisms 2021, 9, 2227. [Google Scholar] [CrossRef]
  37. Spanu, T.; Sanguinetti, M.; Tumbarello, M.; D’Inzeo, T.; Fiori, B.; Posteraro, B.; Santangelo, R.; Cauda, R.; Fadda, G. Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates. J. Clin. Microbiol. 2006, 44, 3257–3262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Wiegand, I.; Geiss, H.K.; Mack, D.; Stürenburg, E.; Seifert, H. Detection of Extended-Spectrum Beta-Lactamases among Enterobacteriaceae by Use of Semiautomated Microbiology Systems and Manual Detection Procedures. J. Clin. Microbiol. 2007, 45, 1167–1174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Clermont, O.; Condamine, B.; Dion, S.; Gordon, D.M.; Denamur, E. The E Phylogroup of Escherichia coli Is Highly Diverse and Mimics the Whole E. Coli Species Population Structure. Environ. Microbiol. 2021, 23, 7139–7151. [Google Scholar] [CrossRef] [PubMed]
  40. De Castro Stoppe, N.; Silva, J.S.; Carlos, C.; Sato, M.I.Z.; Saraiva, A.M.; Ottoboni, L.M.M.; Torres, T.T. Worldwide Phylogenetic Group Patterns of Escherichia coli from Commensal Human and Wastewater Treatment Plant Isolates. Front. Microbiol. 2017, 8, 2512. [Google Scholar] [CrossRef] [Green Version]
  41. Coura, F.M.; Diniz, S.D.A.; Silva, M.X.; Mussi, J.M.S.; Barbosa, S.M.; Lage, A.P.; Heinemann, M.B. Phylogenetic Group Determination of Escherichia coli Isolated from Animals Samples. Sci. World J. 2015, 2015, 258424. [Google Scholar] [CrossRef] [Green Version]
  42. Alberca, V.; León, D.; Falcón, N. Keeping Backyard Animals and Evaluation of Knowledge and Practices Associated with Exposure to Zoonotic Agents in La Coipa, Cajamarca, Peru. Rev. Inv. Vet. Perú 2020, 31, e18733. [Google Scholar] [CrossRef]
  43. Benavides, J.A.; Streicker, D.G.; Gonzales, M.S.; Rojas-Paniagua, E.; Shiva, C. Knowledge and Use of Antibiotics among Low-Income Small-Scale Farmers of Peru. Prev. Vet. Med. 2021, 189, 105287. [Google Scholar] [CrossRef]
  44. World Organisation for Animal Health. OIE List Of Antimicrobial Agents Of Veterinary Importance; World Organisation for Animal Health: Paris, France, 2007. [Google Scholar]
  45. Tanfous, F.B.; Alonso, C.A.; Achour, W.; Ruiz-Ripa, L.; Torres, C.; Hassen, A.B. First Description of KPC-2-Producing Escherichia coli and ST15 OXA-48-Positive Klebsiella Pneumoniae in Tunisia. Microb. Drug Resist. 2017, 23, 365–375. [Google Scholar] [CrossRef]
  46. Beyrouthy, R.; Robin, F.; Dabboussi, F.; Mallat, H.; Hamzé, M.; Bonnet, R. Carbapenemase and Virulence Factors of Enterobacteriaceae in North Lebanon between 2008 and 2012: Evolution via Endemic Spread of OXA-48. J. Antimicrob. Chemother. 2014, 69, 2699–2705. [Google Scholar] [CrossRef]
  47. Peng, Z.; Hu, Z.; Li, Z.; Zhang, X.; Jia, C.; Li, T.; Dai, M.; Tan, C.; Xu, Z.; Wu, B.; et al. Antimicrobial Resistance and Population Genomics of Multidrug-Resistant Escherichia coli in Pig Farms in Mainland China. Nat. Commun. 2022, 13, 1116. [Google Scholar] [CrossRef]
  48. Spurbeck, R.R.; Dinh, P.C.; Walk, S.T.; Stapleton, A.E.; Hooton, T.M.; Nolan, L.K.; Kim, K.S.; Johnson, J.R.; Mobley, H.L.T. Escherichia coli Isolates That Carry Vat, Fyua, Chua, and Yfcv Efficiently Colonize the Urinary Tract. Infect. Immun. 2012, 80, 4115–4122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Gonzales-Rodriguez, A.O.; Varillas, S.F.I.; Pastor, H.J.B.; Mitma, Y.L.; Canales, D.H.; Chero, P.A.W.; Gutierrez, C.; Cunza, S.S. Immunological and Biochemical Response from Older Adults with Urinary Tract Infection to Uropathogenic Escherichia coli Virulence Factors. Rev. Peru Med. Exp. Salud Publica 2020, 37, 527–531. [Google Scholar] [CrossRef] [PubMed]
  50. Zhang, W.; Berberov, E.M.; Freeling, J.; He, D.; Moxley, R.A.; Francis, D.H. Significance of Heat-Stable and Heat-Labile Enterotoxins in Porcine Colibacillosis in an Additive Model for Pathogenicity Studies. Infect. Immun. 2006, 74, 3107–3114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Zeng, S.; Luo, J.; Li, X.; Zhuo, C.; Wu, A.; Chen, X.; Huang, L.S. Molecular Epidemiology and Characteristics of CTX-M-55 Extended-Spectrum β-Lactamase-Producing Escherichia coli From Guangzhou, China. Front. Microbiol. 2021, 12, 730012. [Google Scholar] [CrossRef] [PubMed]
  52. Zhang, C.Z.; Ding, X.M.; Lin, X.L.; Sun, R.Y.; Lu, Y.W.; Cai, R.M.; Webber, M.A.; Ding, H.Z.; Jiang, H.X. The Emergence of Chromosomally Located BlaTX-M-55 in Salmonella from Foodborne Animals in China. Front. Microbiol. 2019, 10, 1268. [Google Scholar] [CrossRef] [PubMed]
  53. Moffat, J.; Chalmers, G.; Reid-Smith, R.; Mulvey, M.R.; Agunos, A.; Calvert, J.; Cormier, A.; Ricker, N.; Weese, J.S.; Boerlin, P. Resistance to Extended-Spectrum Cephalosporins in Escherichia coli and Other Enterobacterales from Canadian Turkeys. PLoS ONE 2020, 15, e0236442. [Google Scholar] [CrossRef]
  54. Norizuki, C.; Wachino, J.I.; Suzuki, M.; Kawamura, K.; Nagano, N.; Kimura, K.; Arakawa, Y. Specific BlaCTX-M-8/IncI1 Plasmid Transfer among Genetically Diverse Escherichia coli Isolates between Humans and Chickens. Antimicrob. Agents Chemother. 2017, 61, e00663-17. [Google Scholar] [CrossRef] [Green Version]
  55. National Library of Medicine (US). Reference Gene Catalog; National Library of Medicine: Bethesda, MD, USA, 2022.
  56. Alcock, B.P.; Raphenya, A.R.; Lau, T.T.Y.; Tsang, K.K.; Bouchard, M.; Edalatmand, A.; Huynh, W.; Nguyen, A.L.V.; Cheng, A.A.; Liu, S.; et al. CARD 2020: Antibiotic Resistome Surveillance with the Comprehensive Antibiotic Resistance Database. Nucleic Acids Res. 2020, 48, D517. [Google Scholar] [CrossRef]
  57. Adator, E.H.; Walker, M.; Narvaez-Bravo, C.; Zaheer, R.; Goji, N.; Cook, S.R.; Tymensen, L.; Hannon, S.J.; Church, D.; Booker, C.W.; et al. Whole Genome Sequencing Differentiates Presumptive Extended Spectrum Beta-Lactamase Producing Escherichia coli along Segments of the One Health Continuum. Microorganisms 2020, 8, 448. [Google Scholar] [CrossRef] [Green Version]
  58. Tekele, S.G.; Teklu, D.S.; Tullu, K.D.; Birru, S.K.; Legese, M.H. Extended-Spectrum Beta-Lactamase and AmpC Beta-Lactamases Producing Gram Negative Bacilli Isolated from Clinical Specimens at International Clinical Laboratories, Addis Ababa, Ethiopia. PLoS ONE 2020, 15, e0241984. [Google Scholar] [CrossRef]
  59. Guzmán-Blanco, M.; Labarca, J.A.; Villegas, M.V.; Gotuzzo, E. Extended Spectrum β-Lactamase Producers among Nosocomial Enterobacteriaceae in Latin America. Braz. J. Infect. Dis. 2014, 18, 421–433. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Fuga, B.; Sellera, F.P.; Cerdeira, L.; Esposito, F.; Cardoso, B.; Fontana, H.; Moura, Q.; Cardenas-Arias, A.; Sano, E.; Ribas, R.M.; et al. WHO Critical Priority Escherichia coli as One Health Challenge for a Post-Pandemic Scenario: Genomic Surveillance and Analysis of Current Trends in Brazil. Microbiol. Spectr. 2022, 10, 1–18. [Google Scholar] [CrossRef] [PubMed]
  61. Escandón-Vargas, K.; Reyes, S.; Gutiérrez, S.; Villegas, M.V. The Epidemiology of Carbapenemases in Latin America and the Caribbean. Expert Rev. Anti Infect. Ther. 2017, 15, 277–297. [Google Scholar] [CrossRef] [PubMed]
  62. Cui, X.; Zhang, H.; Du, H. Carbapenemases in Enterobacteriaceae: Detection and Antimicrobial Therapy. Front. Microbiol. 2019, 10, 1823. [Google Scholar] [CrossRef] [PubMed]
  63. Centers for Disease Control and Prevention (CDC). CRE Technical Information. Available online: https://www.cdc.gov/hai/organisms/cre/technical-info.html (accessed on 19 February 2022).
  64. Temkin, E.; Adler, A.; Lerner, A.; Carmeli, Y. Carbapenem-Resistant Enterobacteriaceae: Biology, Epidemiology, and Management. Ann. NY Acad. Sci. 2014, 1323, 22–42. [Google Scholar] [CrossRef]
  65. Marimuthu, K.; Ng, O.T.; Cherng, B.P.Z.; Fong, R.K.C.; Pada, S.K.; De, P.P.; Ooi, S.T.; Smitasin, N.; Thoon, K.C.; Krishnan, P.U.; et al. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae. Antimicrob. Agents Chemother. 2019, 63, e00845-19. [Google Scholar] [CrossRef] [Green Version]
  66. Carattoli, A. Plasmids and the Spread of Resistance. Int. J. Med. Microbiol. 2013, 303, 298–304. [Google Scholar] [CrossRef]
  67. Carattoli, A. Resistance Plasmid Families in Enterobacteriaceae. Antimicrob. Agents Chemother. 2009, 53, 2227–2238. [Google Scholar] [CrossRef] [Green Version]
  68. Ramsamy, Y.; Mlisana, K.P.; Amoako, D.G.; Abia, A.L.K.; Ismail, A.; Allam, M.; Mbanga, J.; Singh, R.; Essack, S.Y. Mobile Genetic Elements-Mediated Enterobacterales-Associated Carbapenemase Antibiotic Resistance Genes Propagation between the Environment and Humans: A One Health South African Study. Sci. Total Environ. 2022, 806, 150641. [Google Scholar] [CrossRef]
  69. Partridge, S.R.; Kwong, S.M.; Firth, N.; Jensen, S.O. Mobile Genetic Elements Associated with Antimicrobial Resistance. Clin. Microbiol. Rev. 2018, 31, e00088-17. [Google Scholar] [CrossRef] [Green Version]
Table
Table 1. Characterisation of the ESBL-producing E. coli isolates according to origin and source, sequence type and clonal complex, serotype, virulence genes, resistance phenotype and genotype, and plasmid type.
Table 1. Characterisation of the ESBL-producing E. coli isolates according to origin and source, sequence type and clonal complex, serotype, virulence genes, resistance phenotype and genotype, and plasmid type.
ID E. coli StrainsSourceST/CCSerotypePhylogroupVirulence GenesResistance PhenotypeResistance GenotypePlasmid Type
1143dog faeces5259/--:H46EastA, chuA, cia, gad, ompT, terCSAM, TZP, KZ, CXM, CTX, CAZ, FEP, MEM, SXTaac(3)-IId, aph(3″)-Ib, aph(6)-Id, aadA1, aadA2, floR, blaTEM-1, blaEC-15, blaCTX-M-8, tet(M), tet(B) dfrA12IncI1-IAlpha, IncR, IncFIB(AP001918), IncFIC(FII)
1144drinking water227/10O9:H10AcapU, cea, cia, fyuA, iutA, sitA, irp2, iroN, terCSAM, TZP, KZ, CXM, CTX, MEM, CN, CIPaph(3′)-IIa, cmlA1, blaCTX-M-55, blaEC-15, fosA3, qnrB19, sul3, tet(B) IncFIB, Col440I, IncFII, IncI1-IAlpha, IncFII(pHN7A8)
Abbreviations: CC, clonal complex; ST, sequence type. Resistance phenotype: SAM, ampicillin/sulbactam; TZP, piperacillin/tazobactam; KZ, cefazolin; CXM, cefuroxime; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; MEM, meropenem; SXT, trimethoprim/sulfamethoxazole; CN, gentamicin; CIP, ciprofloxacin.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Medina-Pizzali, M.L.; Venkatesh, A.; Riveros, M.; Cuicapuza, D.; Salmon-Mulanovich, G.; Mäusezahl, D.; Hartinger, S.M. Whole-Genome Characterisation of ESBL-Producing E. coli Isolated from Drinking Water and Dog Faeces from Rural Andean Households in Peru. Antibiotics 2022, 11, 692. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050692

AMA Style

Medina-Pizzali ML, Venkatesh A, Riveros M, Cuicapuza D, Salmon-Mulanovich G, Mäusezahl D, Hartinger SM. Whole-Genome Characterisation of ESBL-Producing E. coli Isolated from Drinking Water and Dog Faeces from Rural Andean Households in Peru. Antibiotics. 2022; 11(5):692. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050692

Chicago/Turabian Style

Medina-Pizzali, Maria Luisa, Apoorva Venkatesh, Maribel Riveros, Diego Cuicapuza, Gabriela Salmon-Mulanovich, Daniel Mäusezahl, and Stella M. Hartinger. 2022. "Whole-Genome Characterisation of ESBL-Producing E. coli Isolated from Drinking Water and Dog Faeces from Rural Andean Households in Peru" Antibiotics 11, no. 5: 692. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050692

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop